Forbes profiles Glenmark's R&D moves

Forbes profiles Glenmark Pharmaceuticals, the Indian drugmaker that's making the switch from a generics company to an innovative drug developer. CEO Glenn Saldanha has a strategy: develop new drugs through the early stages and license them out to deal-hungry pharma companies looking for later-stage programs. "There's a risk in developing these molecules, and we wanted to pass on this risk," Saldanha tells Forbes. "Plus we've always believed that the real growth is in emerging markets." Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.